Prognosis_in_T2N0M0_stage_I_breast_carcinoma:_a_20-year_follow-up_study._In_a_study_of_prognosis_in_node-negative_breast_carcinoma,_we_investigated_293_T2N0M0_patients_treated_by_mastectomy_and_axillary_dissection_with_a_median_follow-up_of_19.8_years._The_probability_of_surviving_20_years_considering_all_causes_of_death_was_41.3%_+/-_3.0%._Recurrence-free_survival_(Kaplan-Meier_estimate)_was_68.6%_+/-_3%_at_10_years_and_63.2%_+/-_3.1%_at_20_years._The_estimated_probability_of_cure_determined_by_the_method_of_Brinkley_and_Haybittle_was_63%_(95%_confidence_interval_Cl,_55%_to_72%)._Prognosis_was_related_to_primary_tumor_size_with_the_best_separation_(P_=_.06)_when_tumors_from_2.1_to_3.0_cm_(33%_chance_of_recurrence_at_20_years)_and_from_3.1_to_5.0_cm_(44%_chance_of_recurrence_at_20_years)_were_compared._The_histologic_tumor_type_was_prognostically_important._Recurrence_at_20_years_was_not_significantly_different_for_patients_with_invasive_duct_(34%)_and_lobular_(42%)_carcinoma._Women_with_special_types_(medullary,_mucinous,_papillary,_etc)_of_carcinoma_had_a_25%_chance_of_recurrence._Subsequent_contralateral_breast_carcinoma_was_diagnosed_in_29_patients,_and_four_of_these_were_fatal,_accounting_for_only_4.6%_of_breast_carcinoma_deaths._Thirty-two_patients_(10.9%)_developed_a_nonmammary_malignant_neoplasm_(NMMN)_after_the_ipsilateral_breast_carcinoma,_and_69%_of_these_lesions_were_fatal._Although_the_chances_of_recurrence_at_20_years_related_to_tumor_size_and_type_did_not_differ_statistically_in_the_series,_there_were_trends_that_suggest_that_T2N0M0_patients_can_be_stratified_into_recurrence_risk_groups_based_on_tumor_size_and_histologic_type._These_factors_should_be_taken_into_consideration_in_the_design_and_analysis_of_clinical_adjuvant_therapy_trials._Measures_for_the_early_detection_of_common_NMMNs_should_be_included_in_the_routine_follow-up_of_T2N0M0_breast_carcinoma_patients.